Post Authorization Safety Study (PASS) among Patients Treated with Flixabi for Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Other Spondyloarthropathies (SpA), and Psoriatic Arthritis (PsA) within the Swedish, Population based, Anti-Rheumatic Therapies in Sweden (ARTIS) register. (Safety of Flixabi in ARTIS)